Ann: December 2021 Quarterly Update and Appendix 4C, page-7

You can bet your bottom dollar that PTX will be putting OmniCAR through its optimised paces asap... esp if we have made inroads in our pursuit for collaborators and partners. Since the following statement from Bec in mid-Oct, PTX has presented at 6 conferences and had 100 meetings just in the last 3 weeks according to Steve in the webinar....

Prescient’s Director of Scientific Affairs, Dr Rebecca Lim, said, “Critical features of OmniCAR have
been tested in recent months and the data continue to be extremely positive. Our most recent work
conducted in collaboration with the Peter MacCallum Cancer Centre showed that OmniCAR-T cells begin
antigen-directed killing of tumour cells in vitro as soon as they are armed. The team also showed that
OmniCAR-T cells could be re-armed and continue to kill tumour cells without loss of cytotoxicity.
Excitingly, we saw for the first time the real-time ‘switchability’ of the OmniCAR system where the tumour
killing ability of the OmniCAR-T cells could be redirected towards a different antigen through the addition
of a different binder. These early wins are extremely encouraging, and we look forward to the next phase
of pre-clinical testing where the OmniCAR technology will be put through its paces using gold standard
cancer models.”

There'd be some chomping on the bit going on to get OmniCAR to clinical trials, if we have several interested 3rd parties awaiting data from optimised pre-clinical testing! Bring it on!! Maybe thats why the Business Development Manager at Cytiva instructed the Product Manager at ASEAN at Cytiva to connect with our Head of Scientific Affairs back in September. I believe that was in the leadup to Bec presenting at the Asian Cell & Gene Therapy Conference.